{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:05:23Z","timestamp":1786993523491,"version":"build-2736575974"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NIH\/NCI Cancer Center Support Grant","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":["jsm.jsexmed.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Premature ejaculation (PE) is a common sexual dysfunction for which selective serotonin reuptake inhibitors (SSRIs) have been used effectively for treatment. However, compliance with therapy and predictors of long-term SSRI use in the treatment of PE are not well known.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To analyze our experience with drop-out rates with fluoxetine in the primary PE population and to identify predictors of continued use of this agent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Men with primary PE constituted who used fluoxetine and had at least 12 months follow-up constituted the study population. Subjects underwent a comprehensive interview to ascertain self-reported (non-stopwatch) intravaginal ejaculatory latency time (IELT), self-rated control over ejaculation, and personal and patient-reported partner distress due to PE. Patients were treated with fluoxetine 20 mg daily, with the possibility of dose titration up or down based on efficacy and side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes<\/jats:title>\n                    <jats:p>The PE parameters of interest included self-reported IELT, self-rated control over ejaculation, personal and partner distress due to PE, and medication adherence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>130 men were included in the study. Dropout rates at 6 and 12 months were 56% and 72%. Self-rated \u201cpoor\u201d ejaculatory control decreased from 98%\u201341% (P &amp;lt; .01), high personal distress from 47%\u201311% (P\u00a0&amp;lt;\u00a0.01), and high partner distress rates from 72%\u201327% (P &amp;lt; .01). Predictors of continued use at 12 months included high partner distress, being unpartnered, and having a post-treatment IELT \u22655 minutes (P &amp;lt; .01). Overall side effects included headache (5%), dizziness (4%), nausea (5%), nervousness (5%), and sleepiness (8%); however, moderate to severe side effects reported included nausea (2%), sleepiness (2%), headache (2%), and dizziness (2%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Implications<\/jats:title>\n                    <jats:p>Compliance with SSRIs is a well-described problem in the depression literature, but data are sparse regarding continued use of SSRIs in the treatment of PE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Strengths and Limitations<\/jats:title>\n                    <jats:p>We report on 12-month compliance with SSRIs for the treatment of PE. Our early compliance rates were more encouraging than what has been reported in the past. However, IELT was self-reported and not measured objectively, and we did not use validated patient-reported outcomes but rather self-reported ejaculatory control and distress levels, which have limitations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Fluoxetine is an effective agent for the treatment of PE with significant improvement realized in IELT, ejaculatory control, and distress levels for both men and their partners. Despite its efficacy, continued use of fluoxetine beyond 6 months is poor.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.jsxm.2019.09.017","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T21:07:43Z","timestamp":1573765663000},"page":"1895-1899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Compliance With Fluoxetine Use in Men With Primary Premature Ejaculation"],"prefix":"10.1093","volume":"16","author":[{"given":"Lawrence C.","family":"Jenkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raanan","family":"Tal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Guhring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Mulhall","sequence":"additional","affiliation":[{"name":"Sexual & Reproductive Medicine Program, Urology Service, Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,11,14]]},"reference":[{"key":"2023012309483023000_bib1","first-page":"1065","article-title":"The psychological burden of premature ejaculation","volume":"177","author":"Rowland","year":"2007","journal-title":"J\u00a0Urol"},{"key":"2023012309483023000_bib2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1001\/jama.281.6.537","article-title":"Sexual dysfunction in the United States: Prevalence and Predictors","volume":"281","author":"Laumann","year":"1999","journal-title":"JAMA"},{"key":"2023012309483023000_bib3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/01.mou.0000182327.79572.fd","article-title":"Epidemiology of premature ejaculation","volume":"15","author":"Jannini","year":"2005","journal-title":"Curr Opin Urol"},{"key":"2023012309483023000_bib4","first-page":"1423","article-title":"An evidence-based unified definition of lifelong and acquired premature ejaculation: Report of the Second International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation","volume":"11","author":"Serefoglu","year":"2014","journal-title":"J\u00a0Sex Med"},{"key":"2023012309483023000_bib5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00007611-195604000-00008","article-title":"Premature ejaculation: A new approach","volume":"49","author":"Semans","year":"1956","journal-title":"South Med J"},{"key":"2023012309483023000_bib6","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1464-410X.2008.07719.x","article-title":"The pharmacological treatment of premature ejaculation","volume":"102","author":"Giuliano","year":"2008","journal-title":"BJU Int"},{"key":"2023012309483023000_bib7","first-page":"2707","article-title":"Oral agents for the treatment of premature ejaculation: Review of efficacy and safety in the context of the recent International Society for Sexual Medicine Criteria for Lifelong Premature Ejaculation","volume":"8","author":"McMahon","year":"2011","journal-title":"J\u00a0Sex Med"},{"key":"2023012309483023000_bib8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/sj.ijir.3901172","article-title":"Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: A systematic review and meta-analysis","volume":"16","author":"Waldinger","year":"2004","journal-title":"Int J Impot Res"},{"key":"2023012309483023000_bib9","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000112607","article-title":"Tadalafil and fluoxetine in premature ejaculation: Prospective, randomized, double-blind, placebo-controlled study","volume":"80","author":"Mattos","year":"2008","journal-title":"Urol Int"},{"key":"2023012309483023000_bib10","first-page":"1631","article-title":"The efficacy of fluoxetine in the treatment of premature ejaculation: A double-blind placebo controlled study","volume":"156","author":"Kara","year":"1996","journal-title":"J\u00a0Urol"},{"key":"2023012309483023000_bib11","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.eururo.2009.01.025","article-title":"Dapoxetine for the treatment of premature ejaculation: Results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries","volume":"55","author":"Buvat","year":"2009","journal-title":"Eur Urol"},{"key":"2023012309483023000_bib12","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(06)69373-2","article-title":"Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: An integrated analysis of two double-blind, randomised controlled trials","volume":"368","author":"Pryor","year":"2006","journal-title":"Lancet"},{"key":"2023012309483023000_bib13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/bmj.330.7488.385","article-title":"Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: Meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's Safety Review","volume":"330","author":"Gunnell","year":"2005","journal-title":"BMJ"},{"key":"2023012309483023000_bib14","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/bmj.330.7488.396","article-title":"Association between suicide attempts and selective serotonin reuptake inhibitors: Systematic review of randomised controlled trials","volume":"330","author":"Fergusson","year":"2005","journal-title":"BMJ"},{"key":"2023012309483023000_bib15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/ebmh.9.3.65","article-title":"Early discontinuation of antidepressant treatment in adults is very common in the USA","volume":"9","author":"Andersson","year":"2006","journal-title":"Evid Based Ment Health"},{"issue":"Suppl. 1","key":"2023012309483023000_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/(SICI)1520-6394(1998)7:1+<11::AID-DA4>3.0.CO;2-I","article-title":"SSRIs versus tricyclic antidepressants in depressed inpatients: A meta-analysis of efficacy and tolerability","volume":"7","author":"Anderson","year":"1998","journal-title":"Depress Anxiety"},{"key":"2023012309483023000_bib17","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1136\/bmj.310.6992.1433","article-title":"Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: A meta-analysis","volume":"310","author":"Anderson","year":"1995","journal-title":"BMJ"},{"key":"2023012309483023000_bib18","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.clinthera.2008.08.014","article-title":"Role of patient experience in antidepressant adherence: A retrospective data analysis","volume":"30","author":"Vanelli","year":"2008","journal-title":"Clin Ther"},{"key":"2023012309483023000_bib19","first-page":"524","article-title":"Efficacy and safety of dapoxetine for the treatment of premature ejaculation: Integrated analysis of results from five phase 3 trials","volume":"8","author":"McMahon","year":"2011","journal-title":"J\u00a0Sex Med"},{"key":"2023012309483023000_bib20","first-page":"358","article-title":"Premature ejaculation: An observational study of men and their partners","volume":"2","author":"Patrick","year":"2005","journal-title":"J\u00a0Sex Med"},{"key":"2023012309483023000_bib21","first-page":"107","article-title":"The effects of fluoxetine on several neurophysiological variables in patients with premature ejaculation","volume":"161","author":"Yilmaz","year":"1999","journal-title":"J\u00a0Urol"},{"key":"2023012309483023000_bib22","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1097\/00029330-200706010-00011","article-title":"Selective serotonin reuptake inhibitors in the treatment of premature ejaculation","volume":"120","author":"Wang","year":"2007","journal-title":"Chin Med J"},{"key":"2023012309483023000_bib23","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.eururo.2007.10.015","article-title":"Premature ejaculation: Results from a five-country european observational study","volume":"53","author":"Giuliano","year":"2008","journal-title":"Eur Urol"},{"key":"2023012309483023000_bib24","first-page":"123","article-title":"Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or snri antidepressants in commercial health plans","volume":"17","author":"Vlahiotis","year":"2011","journal-title":"J\u00a0Manag Care Pharm"},{"key":"2023012309483023000_bib25","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archpsyc.55.12.1128","article-title":"The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression","volume":"55","author":"Melfi","year":"1998","journal-title":"Arch Gen Psychiatr"},{"key":"2023012309483023000_bib26","doi-asserted-by":"crossref","first-page":"727","DOI":"10.4088\/JCP.v63n0811","article-title":"Antidepressant medication management and health plan employer data information set (HEDIS) criteria: reasons for nonadherence","volume":"63","author":"Kobak","year":"2002","journal-title":"J\u00a0Clin Psychiatr"},{"key":"2023012309483023000_bib27","first-page":"2868","article-title":"Acceptance of and discontinuation rate from paroxetine treatment in patients with lifelong premature ejaculation","volume":"6","author":"Salonia","year":"2009","journal-title":"J\u00a0Sex Med"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609519314456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609519314456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/16\/12\/1895\/48589277\/jsm_16_12_1895.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/16\/12\/1895\/48589277\/jsm_16_12_1895.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T05:26:22Z","timestamp":1674451582000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/16\/12\/1895\/6980657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,14]]},"references-count":27,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,11,14]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jsxm.2019.09.017","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2019,12]]},"published":{"date-parts":[[2019,11,14]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Compliance With Fluoxetine Use in Men With Primary Premature Ejaculation","name":"articletitle","label":"Article Title"},{"value":"The Journal of Sexual Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsxm.2019.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society for Sexual Medicine. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}